



CLINICAL AND
LABORATORY
STANDARDS
INSTITUTE®

2nd Edition

M24S

Performance Standards for Susceptibility Testing of *Mycobacteria*, *Nocardia* spp., and Other Aerobic Actinomycetes

Sample

This document includes updated breakpoint and quality control tables for the Clinical and Laboratory Standards Institute susceptibility testing standard M24.

A CLSI supplement for global application.

Performance Standards for Susceptibility Testing of *Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes*

Nicole M. Parrish, PhD, MHS, D(ABMM)
Nancy L. Wengenack, PhD, D(ABMM)
Adam Barker, PhD
Barbara A. Brown-Elliott, MS, MT(ASCP)SM
Daniela Maria Cirillo, MD, PhD
Susan Harrington, PhD, D(ABMM), MLS(ASCP)^{CM}
Reeti Khare, PhD, D(ABMM)
Scott B. Killian, BS
Richard Pfeltz, PhD
Elvira Richter, PhD
Marie-Claire Rowlinson, PhD, D(ABMM)
Adrian M. Zelazny, PhD, D(ABMM)

Abstract

Clinical and Laboratory Standards Institute document M24S—*Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes* includes the minimal inhibitory concentrations and QC ranges developed following the standards described in CLSI document M24.¹ The data in the tables are valid only when the methodology in CLSI document M24¹ is followed.

Clinical and Laboratory Standards Institute (CLSI). *Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes*. 2nd edition. CLSI supplement M24S (ISBN 978-1-68440-168-0 [Print]; ISBN 978-1-68440-169-7 [Electronic]). Clinical and Laboratory Standards Institute, USA, 2023.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org.

If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at:

P: +1.610.688.0100 **F:** +1.610.688.0700 **E:** customerservice@clsi.org **W:** www.clsi.org

Copyright ©2023 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, derivative product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

Suggested Citation

CLSI. *Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes*. 2nd edition. CLSI supplement M24S. Clinical and Laboratory Standards Institute; 2023.

Previous Editions:

M62: November 2018

Sample

M24-Ed3-S-Ed2
ISBN 978-1-68440-168-0 (Print)
ISBN 978-1-68440-169-7 (Electronic)
ISSN 1558-6502 (Print)
ISSN 2162-2914 (Electronic)

Volume 43, Number 2

Contents

Abstract	i
Committee Membership.....	iii
Overview of Changes	vii
Abbreviations and Acronyms	xi
Reference	xii
Table 1. Broth Microdilution Breakpoints and Interpretive Categories for MTBC Tested in Middlebrook 7H9 Broth Supplemented With OADC Using MIC Panels.....	1
Table 2. Susceptibility Testing of MTBC to Second-Line Drugs Using the Fluorescence-based Commercial Shorter-Incubation Liquid Media System.....	3
Table 3. Antimicrobial Agents and Breakpoints for Testing MAC.....	6
Table 4. Antimicrobial Agents and Breakpoints for Testing <i>Mycobacterium kansasii</i>	8
Table 5. Antimicrobial Agents and Breakpoints for Testing Slowly Growing Nontuberculous Mycobacteria Other Than MAC and <i>Mycobacterium kansasii</i>	9
Table 6. Antimicrobial Agents and Breakpoints for Testing Rapidly Growing Mycobacteria	10
Table 7. Antimicrobial Agents and Breakpoints for Testing <i>Nocardia</i> spp. and Other Aerobic Actinomycetes.....	13
Table 8. Expected Antimicrobial Susceptibility Patterns of the Most Commonly Isolated <i>Nocardia</i> spp.....	15
Table 9. Expected Results for Routine and Supplemental QC Strains When Testing MTBC by a Culture-based Method.....	17
Table 10. MIC QC Ranges When Testing MTBC Using <i>Mycobacterium tuberculosis</i> ATCC® 27294 (H37Rv) Tested in Middlebrook 7H9 Medium Supplemented With OADC	18
Table 11. QC Ranges for Susceptibility Testing of <i>Mycobacterium tuberculosis</i> ATCC® 27294 (H37Rv) to Second-Line Drugs Using the Fluorescence-based Commercial Shorter-Incubation Liquid Media System	20
Table 12. Broth Microdilution QC Ranges When Testing Slowly Growing Nontuberculous Mycobacteria in Cation-Adjusted Mueller-Hinton Broth With OADC	21
Table 13. Broth Microdilution QC Ranges When Testing Rapidly Growing Mycobacteria in Cation-Adjusted Mueller-Hinton Broth Without OADC	23

Contents (Continued)

Table 14. Broth Microdilution QC Ranges When Testing *Nocardia* spp. and Other Aerobic Actinomycetes in Cation-Adjusted Mueller-Hinton Broth Without OADC 25

The Quality Management System Approach 27

Sample

.....

Table 1. Broth Microdilution Breakpoints and Interpretive Categories for MTBC Tested in Middlebrook 7H9 Broth Supplemented With OADC Using MIC Panels¹⁻³

QC Recommendation (see Table 10 for acceptable QC ranges)

Routine QC strain:

- *Mycobacterium tuberculosis* ATCC® 27294 (H37Rv)

General Comments

- (1) ATCC® is a registered trademark of the American Type Culture Collection.
- (2) This table contains updated information and notifies laboratories of important changes among published versions of CLSI document M24.⁴
- (3) The breakpoints in Table 1 were established using lyophilized MIC panels incubated in 5% to 10% CO₂. Incubating tests in ambient air may result in erroneous MICs because MTBC grow more slowly in ambient air. If preparing in-house MIC panels, care should be taken to match the manufacturer's formulation because the use of polysorbate or glycerol in the broth may affect the MIC values obtained.
- (4) This antimicrobial susceptibility testing system is not regulatory organization cleared.

NOTE: Information in black boldface type is new or modified since the previous edition.

Antimicrobial Agent	MIC Breakpoints, µg/mL			Comments
	S	Inconclusive ⁵	R	
Ethambutol	≤ 2	4	≥ 8	(5) Inconclusive MIC for ethambutol. An MIC of 4 µg/mL obtained by broth microdilution using lyophilized panels does not correlate with either a susceptible or resistant result in commercial automated, short-incubation broth systems, and there are no clinical data correlating such a result with ethambutol treatment response. NOTE: Repeat testing using an alternative broth method (eg, critical concentration) or genotypic method may determine whether the isolate in question is susceptible or resistant.

Table 6. Antimicrobial Agents and Breakpoints for Testing Rapidly Growing Mycobacteria

QC Recommendations (see Table 13 for acceptable QC ranges)

Routine QC strain:

- *Mycobacterium peregrinum* ATCC® 700686

Supplemental QC strains:

- *Staphylococcus aureus* ATCC® 29213
- *Enterococcus faecalis* ATCC® 29212 and/or *Pseudomonas aeruginosa* ATCC® 27853 may also be used, if desired.

General Comment

(1) ATCC® is a registered trademark of the American Type Culture Collection.

NOTE: Information in black boldface type is new or modified since the previous edition.

Antimicrobial Agent	MIC, µg/mL			Comments
	S	I	R	
Amikacin (IV)	≤ 16	32	≥ 64	(2) If <i>Mycobacterium abscessus</i> isolates have an MIC ≥ 64 µg/mL, they should be retested. The amikacin mutation in the <i>rrs</i> gene may be detected in isolates with higher MICs. If the repeat result is ≥ 64 µg/mL, the MIC should be reported with the comment, “The MIC is greater than expected for this species; if the drug is being considered for therapy, the laboratory should be notified so the isolate can be sent to a referral laboratory for confirmation of resistance.”
Cefoxitin	≤ 16	32-64	≥ 128	
Ciprofloxacin	≤ 1	2	≥ 4	(3) Ciprofloxacin and levofloxacin are interchangeable. Both are less active <i>in vitro</i> than the newer 8-methoxy fluoroquinolones.
Clarithromycin	≤ 2	4	≥ 8	(4) Clarithromycin is the class representative for the newer macrolides (eg, azithromycin, clarithromycin, and roxithromycin). See CLSI document M24 ¹ for guidance regarding incubation period, molecular testing, and interpretation of clarithromycin results for rapidly growing mycobacteria.
Doxycycline	≤ 1	2-4	≥ 8	(5) Minocycline can be substituted.